Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis‐targeting chimeras-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis‐targeting chimeras

Published:2021-06-17 Issue:3 Volume:2 Page:341-350
ISSN:2688-2663
Container-title:MedComm
language:en
Short-container-title:MedComm

Author:

Song Xiaoling¹^ORCID,Zhong Hui¹²,Qu Xiaojuan¹,Yang Linsong²,Jiang Biao¹³

Affiliation:

1. Shanghai institute for advanced immunochemical studies ShanghaiTech University Shanghai China

2. School of pharmaceutical engineering and life science Changzhou University Jiangsu China

3. Chinese academy of sciences Shanghai institute of organic chemistry Shanghai China

Funder

National Natural Science Foundation of China

Science and Technology Commission of Shanghai Municipality

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mco2.42

Reference35 articles.

1. Lung Cancer in People’s Republic of China

2. Cancer statistics, 2019

3. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

4. Drug resistance in ALK-positiveNon-small cell lungcancer patients

5. Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies;Cancer Drug Resistance;2024-05-23

2. Structure-Based Optimization of Pyrazinamide-Containing Macrocyclic Derivatives as Fms-like Tyrosine Kinase 3 (FLT3) Inhibitors to Overcome Clinical Mutations;ACS Pharmacology & Translational Science;2024-04-11

3. Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient;Acta Pharmacologica Sinica;2024-02-15

4. A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations;Frontiers in Molecular Biosciences;2024-01-11

5. Recent Advances in FDA-Approved Kinase Inhibitors Targeting Lung Cancer;Handbook of Oncobiology: From Basic to Clinical Sciences;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3